Metabolic Syndrome

• Insulin Resistance (Central Mechanism): The fundamental defect involves impaired insulin-stimulated glucose uptake primarily in skeletal muscle (40% of glucose disposal), adipose tissue, and liver. At the molecular level, obesity causes chronic infiltration of adipose tissue by pro-inflammatory macrophages and increased free fatty acid (FFA) flux from expanded adipose stores. Elevated FFAs impair insulin signaling through multiple mechanisms: (1) PKC activation displaces insulin receptor substrate-1 (IRS-1) from the insulin receptor, blocking phosphoinositide 3-kinase (PI3K) recruitment and glucose transporter 4 (GLUT4) translocation; (2) lipid metabolites (diacylglycerols and ceramides) activate serine kinases (IKKβ and PKC) that phosphorylate IRS-1 on inhibitory serine residues, preventing tyrosine phosphorylation required for signal transduction; (3) endoplasmic reticulum (ER) stress from lipid overload activates JNK, which further phosphorylates IRS-1. The resulting reduction in insulin-stimulated glucose uptake increases both fasting and postprandial hyperglycemia. Insulin resistance also impairs suppression of hepatic glucose output through defective glycogenesis and increased gluconeogenesis (loss of PI3K signaling in hepatocytes reduces glycogen synthase activation). Adipose tissue insulin resistance causes impaired suppression of hormone-sensitive lipase, leading to increased lipolysis and circulating FFA levels—a vicious cycle perpetuating systemic insulin resistance.

• Dyslipidemia Driven by Hepatic Lipase Dysregulation: Insulin resistance fundamentally alters lipid metabolism through altered hepatic gene transcription and increased substrate availability. Reduced insulin signaling fails to suppress SREBP-1c (sterol regulatory element-binding protein-1c), a transcription factor normally inhibited by phosphorylated Akt; unopposed SREBP-1c activation drives upregulation of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), increasing hepatic de novo lipogenesis (DNL). Simultaneously, increased FFA uptake from adipose tissue provides additional substrate for triglyceride synthesis. The characteristic lipid triad—elevated triglycerides, reduced HDL-C, and increased small dense LDL particles (more atherogenic than large buoyant particles)—reflects both increased VLDL production (from increased DNL) and impaired HDL metabolism. Elevated triglycerides drive hepatic lipase activity, which selectively catabolizes HDL-C, further depressing HDL levels. The small dense LDL phenotype, characteristic of metabolic syndrome, results from remodeling by lipid transfer proteins and lipase activity; these particles penetrate the arterial intima more readily and resist reverse cholesterol transport.

• Systemic Inflammation and Endothelial Dysfunction: Central obesity creates a state of chronic, low-grade inflammation through multiple mechanisms: adipose tissue expansion recruits macrophages (via increased CCL2/MCP-1 and reduced adiponectin signaling), and enlarged adipocytes increase production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) while reducing anti-inflammatory adiponectin and leptin secretion. Hepatic steatosis (non-alcoholic fatty liver disease, NAFLD—present in >80% of metabolic syndrome) further amplifies systemic inflammation through increased lipopolysaccharide (LPS) absorption from dysbiotic gut microbiota and activation of TLR4 signaling pathways. Elevated circulating FFAs activate TLR4 on immune cells and endothelium, promoting NF-κB-dependent inflammatory gene expression. The resulting elevation of CRP, fibrinogen, and IL-6 increases atherothrombotic risk and promotes vascular dysfunction. At the endothelial level, insulin resistance impairs endothelial nitric oxide synthase (eNOS) signaling through reduced Akt-mediated activation and increased uncoupling eNOS (which produces superoxide rather than NO in the context of reduced cofactor availability and oxidative stress). Reduced bioavailable NO promotes vasoconstriction, increases vascular permeability, and facilitates LDL oxidation and subintimal accumulation. Chronic hyperinsulinemia (compensatory response to insulin resistance) directly increases sympathetic tone and sodium reabsorption in the collecting duct through ENAC stimulation, contributing to hypertension.

• Hypertension in Metabolic Syndrome: Multiple mechanisms converge to increase blood pressure. Hyperinsulinemia activates the sympathetic nervous system through enhanced activity of the rostral ventrolateral medulla and increased norepinephrine reuptake inhibition. At the renal level, insulin stimulates sodium reabsorption in the proximal tubule and collecting duct (via stimulation of Na-K-ATPase and epithelial sodium channel); impaired NO production reduces natriuretic peptide responsiveness. Angiotensin II, elevated in many with metabolic syndrome through activation of the renin-angiotensin-aldosterone system (RAAS) in response to reduced renal perfusion and sympathetic activation, contributes to salt retention and vascular stiffness. Additionally, oxidative stress and endothelial dysfunction reduce vasodilatory capacity, and increased sympathetic outflow further elevates peripheral vascular resistance.

• Visceral Adiposity as the Key Anatomical Driver: Central (visceral) obesity, not total body fat mass, is the critical pathophysiologic driver of metabolic syndrome. Visceral adipocytes are metabolically distinct from subcutaneous adipocytes—they exhibit greater insulin resistance, higher lipolytic rates, enhanced inflammatory cytokine production, and greater leptin resistance. The portal circulation drains visceral fat directly to the liver via short hepatic vessels, delivering high concentrations of FFAs and inflammatory mediators (IL-6, TNF-α) preferentially to hepatocytes. This anatomical arrangement explains why visceral adiposity predicts fatty liver disease, dyslipidemia, and systemic inflammation more strongly than peripheral adiposity. The hepatic lipid overload triggers hepatocellular insulin resistance, impairs gluconeogenic suppression, and amplifies VLDL production.

• Genetic Predisposition: Twin studies demonstrate 40-60% heritability for metabolic syndrome components. Candidate genes include those affecting adiponectin signaling (ADIPOQ mutations), inflammatory pathways (IL-6, TNF-α polymorphisms), and lipid metabolism (LIPC, APOE, LDLR variants). However, metabolic syndrome represents a polygenic inheritance pattern with small individual effect sizes; no single genetic test predicts syndrome development. Environmental modulation (diet, physical activity) can overwhelm genetic predisposition in many individuals, explaining the dramatic increase in prevalence with westernization of populations.

• Central Obesity (Primary Driver): Expansion of visceral adipose stores is the most direct modifiable risk factor for metabolic syndrome development. Increased caloric intake (particularly refined carbohydrates and fructose) combined with sedentary lifestyle promotes weight gain preferentially in the visceral compartment through multiple mechanisms including altered lipid partitioning, increased hepatic de novo lipogenesis, and impaired lipid oxidation. Fructose is particularly metabolically harmful—unlike glucose, fructose phosphorylation by fructokinase bypasses phosphofructokinase (the rate-limiting enzyme of glycolysis), driving unregulated hepatic lipogenesis and bypassing satiety signals.

• Insulin Resistance (Genetic and Acquired): Genetic factors predisposing to insulin resistance at the cellular level (involving INSR, IRS-1, PI3K, and GLUT4 polymorphisms) interact with acquired causes including chronic inflammation, increased circulating FFAs, mitochondrial dysfunction, and ER stress. Mitochondrial dysfunction (reduced oxidative phosphorylation capacity, increased ROS production) impairs lipid oxidation and ATP generation in skeletal muscle, promoting lipid accumulation and insulin resistance. Some individuals possess genetic variants promoting "metabolically unhealthy obesity" despite normal BMI (termed "metabolically obese, normal-weight" individuals), driven by differential lipid partitioning and mitochondrial function.

• Sedentary Lifestyle: Physical inactivity reduces insulin-stimulated GLUT4 translocation in skeletal muscle (the largest glucose-consuming organ), promotes weight gain particularly in visceral compartment, reduces HDL-C clearance capacity, and impairs lipid oxidation in muscle. Conversely, even modest aerobic and resistance exercise improves insulin sensitivity independent of weight loss through AMPK activation, mitochondrial biogenesis, and enhanced GLUT4 expression.

• Dietary Factors (High Glycemic Load, Trans Fats, Excessive Fructose): Refined carbohydrates with high glycemic index/glycemic load (white bread, sugar-sweetened beverages) cause rapid glucose and insulin spikes, promoting hepatic DNL and visceral fat deposition. Trans fats increase systemic inflammation, reduce HDL-C, increase small dense LDL, and impair endothelial function. Excessive fructose consumption (from added sugars and high-fructose corn syrup) uniquely promotes hepatic lipogenesis and triglyceride accumulation independent of total calorie intake.

• Aging: Metabolic syndrome prevalence increases sharply after age 40 due to accumulating insulin resistance (sarcopenia reduces glucose disposal capacity, mitochondrial dysfunction accelerates), decreased sex hormone levels (testosterone and estrogen promote insulin sensitivity and have anti-inflammatory effects), and accumulated metabolic inflammation.

• Ethnic and Genetic Predisposition: Hispanic, Native American, South Asian, and African American populations demonstrate higher metabolic syndrome prevalence at lower BMI thresholds, reflecting both genetic predisposition to visceral adiposity and differential metabolic responses to obesity. South Asian populations in particular develop metabolic syndrome at BMI 23-25 kg/m², necessitating lower BMI cutoffs for this group.

• Endocrine Disorders (Secondary Causes): Polycystic ovary syndrome (PCOS) presents in 20-40% of metabolic syndrome cases in women, with shared pathophysiology of insulin resistance, androgen excess, and visceral adiposity. Cushing's syndrome, through elevated glucocorticoid levels, promotes visceral adiposity accumulation, insulin resistance, hypertension, and dyslipidemia. Hypothyroidism reduces energy expenditure and promotes weight gain. Hypogonadism in men (whether primary or secondary) increases visceral adiposity and worsens insulin sensitivity.

• Sleep Disorders: Sleep deprivation and obstructive sleep apnea (OSA) independently promote metabolic syndrome through multiple mechanisms—increased nocturnal sympathetic outflow (OSA), impaired cortisol regulation, increased ghrelin and decreased leptin (sleep deprivation), and chronic intermittent hypoxia (OSA) driving inflammation.

• Medications: Atypical antipsychotics (particularly clozapine and olanzapine), corticosteroids (especially at high doses), thiazide diuretics (at higher doses >12.5 mg daily), beta-blockers (non-selective agents like propranolol, though less so with beta-1 selective agents like metoprolol), and protease inhibitors contribute to metabolic syndrome through weight gain, insulin resistance, or dyslipidemia.

• Chronic Inflammation and Infection: Chronic infections (HIV, hepatitis C), inflammatory bowel disease, and chronic kidney disease promote systemic inflammation and accelerate metabolic syndrome development.

• Cardinal Feature: Central/Abdominal Obesity: Patients present with increased waist circumference reflecting visceral adiposity accumulation—typically described as "apple-shaped" distribution with abdominal protuberance despite relatively normal limb mass. The pathophysiology directly links this anatomical distribution to hepatic lipid overload, systemic inflammation, and endothelial dysfunction. Waist circumference thresholds for diagnosis are ethnicity-specific (≥40 inches in men and ≥35 inches in women of European descent; ≥37 inches in men and ≥31.5 inches in women of South Asian descent).

• Metabolic Complaints and Fatigue: Many patients report nonspecific fatigue, reduced exercise tolerance, and difficulty losing weight despite calorie restriction—reflecting underlying mitochondrial dysfunction, chronic inflammation, and reduced metabolic flexibility. Postprandial somnolence (particularly after high-glycemic meals) relates to exaggerated insulin secretion and transient hypoglycemia following initial hyperglycemia.

• Glycemic Dysfunction: Patients may be asymptomatic regarding glucose abnormalities in early stages, but fasting hyperglycemia (impaired fasting glucose 100-125 mg/dL or frank diabetes with fasting glucose ≥126 mg/dL) reflects hepatic insulin resistance and unopposed gluconeogenesis. Some patients report polydipsia and polyuria if fasting glucose exceeds 200 mg/dL with glycosuria.

• Hypertension-Related Symptoms: Many present with newly diagnosed hypertension (BP ≥130/85 mmHg), often responsive to weight loss and exercise but potentially requiring pharmacotherapy. Headaches, dizziness, or palpitations may occur with more severely elevated blood pressure. The hypertension typically develops silently without symptoms, potentially detected incidentally on routine exam or when patients present with cardiovascular complications.

• Lipid-Related Presentations: Patients typically have no symptoms directly related to dyslipidemia, which is discovered only on laboratory testing. However, those with pre-existing atherosclerotic disease may present with accelerated angina pectoris or increased myocardial infarction (MI) risk reflecting the atherogenic small dense LDL pattern. Rarely, extremely elevated triglycerides (>1000 mg/dL) can cause eruptive xanthomas or lipemic retinalis.

• Physical Examination Findings:
• Central adiposity with increased waist circumference (measured at the level of the iliac crest) often with relative sparing of extremities
• Hypertension (≥130/85 mmHg, though many are unaware)
• Acanthosis nigricans (darkened, velvety skin patches typically in neck, axillae, inguinal folds)—present in 40-60% of metabolic syndrome patients, reflecting severe insulin resistance and often signaling additional endocrine abnormalities (PCOS, Cushing's syndrome)
• Skin tags associated with acanthosis nigricans and insulin resistance
• Xanthelasmas (yellowish deposits around eyelids) suggesting dyslipidemia
• Hepatomegaly present in 60-80% due to hepatic steatosis (non-alcoholic fatty liver disease)

• Important Clinical Variants:
• "Metabolically obese, normal-weight" individuals (BMI <25 kg/m²) with visceral adiposity and metabolic syndrome features—often missed clinically because BMI appears normal; central adiposity and inflammatory markers provide clues to diagnosis
• Lean metabolic syndrome occurring in 10-15% of patients with BMI <25 kg/m², particularly in Asian populations with genetic predisposition to visceral fat accumulation and metabolic dysfunction
• Rapid-onset metabolic syndrome following initiation of atypical antipsychotics or high-dose corticosteroids, with weight gain >5-10 kg in weeks to months

• IDF (International Diabetes Federation) Criteria (Most Widely Used): Diagnosis requires central obesity (waist circumference ≥94 cm in European men, ≥80 cm in European women; thresholds vary by ethnicity) PLUS any two of the following four criteria: (1) triglycerides ≥150 mg/dL or on triglyceride-lowering therapy; (2) HDL-C <40 mg/dL in men or <50 mg/dL in women or on HDL-raising

First-line — intensive lifestyle therapy (the backbone of every guideline)

• Weight loss: the AHA/NHLBI scientific statement on metabolic syndrome and the AHA/ACC/TOS obesity guideline target sustained loss of roughly 5–10% of body weight, which disproportionately mobilizes visceral fat and reverses portal free-fatty-acid delivery, improving all five syndrome components at once.
• Physical activity: at least 150 minutes/week of moderate-intensity aerobic activity plus resistance training (ADA Standards of Care). Contraction-induced AMPK activation and GLUT4 translocation improve insulin sensitivity independent of weight loss.
• Diet: Mediterranean-style or DASH pattern with restriction of added sugars/fructose and refined carbohydrate; the Diabetes Prevention Program showed lifestyle change outperformed metformin in preventing progression to type 2 diabetes.

Component-directed pharmacotherapy

• Statins (e.g., moderate- to high-intensity atorvastatin): per the 2018 ACC/AHA cholesterol guideline, metabolic syndrome is a risk-enhancing factor that favors statin therapy when 10-year ASCVD risk by the Pooled Cohort Equations is borderline/intermediate. It is not a "CHD risk equivalent" — that is retired ATP III language.
• Antihypertensives: 2017 ACC/AHA guideline targets <130/80 mmHg; ACE inhibitors or ARBs (e.g., lisinopril) are preferred with diabetes or albuminuria, and may modestly improve insulin sensitivity.
• Metformin: ADA recommends considering it for prediabetes, particularly BMI ≥35 kg/m², age <60, or prior gestational diabetes.
• Incretin-based and SGLT2 agents: GLP-1 receptor agonists (semaglutide) or GIP/GLP-1 agonists (tirzepatide) for obesity with weight-related comorbidity; SGLT2 inhibitors when diabetes with ASCVD, heart failure, or CKD coexists.
• Severe hypertriglyceridemia: with triglycerides in the pancreatitis range, a fibrate (fenofibrate) or icosapent ethyl takes priority over LDL lowering.

Definitive/escalation

• Metabolic and bariatric surgery: ASMBS/IFSO endorse surgery at BMI ≥35 kg/m² regardless of comorbidity and at ≥30 kg/m² with metabolic disease; sleeve gastrectomy and Roux-en-Y bypass produce weight-independent incretin-mediated remission of hyperglycemia.

Contraindicated/avoid

• ACE inhibitors and ARBs in pregnancy (all of them, including captopril — fetal renal injury).
• Gemfibrozil with a statin (markedly increased myopathy risk); use fenofibrate if combination is needed.
• Niacin added to statin therapy is no longer recommended for HDL raising — outcome trials showed no benefit and excess harm.

Complications of the disease

• Type 2 diabetes mellitus: progressive beta-cell failure superimposed on insulin resistance; signaled by rising fasting glucose and HbA1c. Metabolic syndrome confers several-fold increased risk.
• Atherosclerotic cardiovascular disease: small dense LDL penetrates and is retained in the intima, while low HDL impairs reverse cholesterol transport and endothelial dysfunction reduces NO bioavailability. Acute coronary syndrome and ischemic stroke are emergencies — new chest pain or focal deficit demands immediate ECG/imaging.
• MASLD/NAFLD progressing to steatohepatitis, cirrhosis, and hepatocellular carcinoma: portal delivery of free fatty acids drives steatosis; signaled by mildly elevated ALT (typically ALT > AST until fibrosis develops) and hepatic steatosis on ultrasound. AASLD guidance recommends noninvasive fibrosis risk stratification (e.g., FIB-4) rather than reflex biopsy.
• Hypertriglyceridemia-induced acute pancreatitis: an emergency; suspect with severe epigastric pain, lipemic serum, and a spuriously normal-appearing amylase.
• Chronic kidney disease: glomerular hyperfiltration, hypertension, and albuminuria; screen with urine albumin-to-creatinine ratio.
• Obstructive sleep apnea, hyperuricemia/gout, PCOS with infertility, and a prothrombotic state (elevated PAI-1 and fibrinogen) round out the syndrome's downstream burden.

Complications of treatment

• Statins: myalgia and transaminase elevation; rhabdomyolysis is an emergency — muscle pain with markedly elevated CK and pigmenturia, risk amplified by gemfibrozil or CYP3A4 inhibitors.
• Metformin: GI intolerance and vitamin B12 deficiency (check for macrocytosis/neuropathy); lactic acidosis is rare but an emergency, typically in the setting of acute kidney injury or hypoxia.
• SGLT2 inhibitors: genital mycotic infection, volume depletion, and euglycemic DKA — an emergency with anion-gap acidosis and only mildly elevated glucose; Fournier gangrene is rare but surgical.
• GLP-1 receptor agonists: nausea, delayed gastric emptying (aspiration risk with sedation), pancreatitis; contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.
• Bariatric surgery: early anastomotic leak is an emergency — unexplained tachycardia is the most sensitive sign; later, dumping syndrome and deficiencies of iron, B12, and thiamine (Wernicke encephalopathy after protracted vomiting).

• Three of five is the classic exam framework: increased waist circumference, triglycerides ≥150 mg/dL, HDL <40 mg/dL (men) or <50 mg/dL (women), BP ≥130/85 mmHg, fasting glucose ≥100 mg/dL. The IDF variant makes central obesity mandatory; either way, waist circumference — not BMI — is the measurement being tested.
• Single best next step in an asymptomatic patient meeting criteria: intensive lifestyle modification with a 5–10% weight-loss goal, not immediate polypharmacy. Drugs are added for the individual components that fail to normalize.
• The association examiners love: acanthosis nigricans and skin tags in the axilla/neck as the visible marker of hyperinsulinemia. In an adult with new-onset acanthosis nigricans and weight loss, think instead of an occult gastric adenocarcinoma (paraneoplastic).
• Buzzword pathophysiology: elevated triglycerides + low HDL + small dense LDL is the atherogenic triad; low adiponectin and high PAI-1, CRP, and IL-6 are the classic biomarker pattern.
• The distractor to avoid: calling metabolic syndrome a "CHD risk equivalent." Under the 2018 ACC/AHA cholesterol guideline it is a risk-enhancing factor that tips a borderline/intermediate Pooled Cohort Equation risk toward statin therapy.
• Fructose trick question: fructokinase-mediated metabolism bypasses phosphofructokinase-1, so hepatic lipogenesis proceeds unregulated — the reason sugar-sweetened beverages are singled out.
• Drug-induced metabolic syndrome: olanzapine and clozapine are the highest-risk antipsychotics; the APA recommends baseline and serial weight, lipid, and glucose monitoring after starting them.
• Do not forget the liver: MASLD/NAFLD accompanies most cases; a mildly elevated ALT with a fatty liver on ultrasound in a patient with central obesity is metabolic syndrome until proven otherwise — but still exclude alcohol, viral hepatitis, and hemochromatosis before labeling it.